{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:45:54Z","timestamp":1775598354312,"version":"3.50.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Retinopathy of prematurity (ROP) is a leading cause of blindness in children worldwide. Blindness can occur from retinal detachment caused by pathologic retinal angiogenesis into the vitreous, termed intravitreal neovascularization (IVNV). Although agents that interfere with the bioactivity of vascular endothelial growth factor (VEGF) are now used to treat IVNV, concerns exist regarding the identification of optimal doses of anti-VEGF for individual infants and the effect of broad VEGF inhibition on physiologic angiogenesis in external organs or in the retina of a preterm infant. Therefore, it is important to understand VEGF signaling in both physiologic and pathologic angiogenesis in the retina. In this manuscript, we review the role of receptors that interact with VEGF in oxygen-induced retinopathy (OIR) models that represent features of ROP pathology. Specifically, we discuss our work regarding the regulation of VEGFR2 signaling in retinal endothelial cells to not only reduce severe ROP but also facilitate physiologic retinal vascular and neuronal development.<\/jats:p>","DOI":"10.3389\/fped.2021.796143","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:59:05Z","timestamp":1639054745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Vascular Endothelial Growth Factor Signaling in Models of Oxygen-Induced Retinopathy: Insights Into Mechanisms of Pathology in Retinopathy of Prematurity"],"prefix":"10.3389","volume":"9","author":[{"given":"Aniket","family":"Ramshekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.semperi.2019.05.001","article-title":"Retinopathy of prematurity - a world update","volume":"43","author":"Darlow","year":"2019","journal-title":"Semin Perinatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1136\/bjo.38.7.397","article-title":"Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia","volume":"38","author":"Ashton","year":"1954","journal-title":"Br J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"Cd009734","DOI":"10.1002\/14651858.CD009734.pub3","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B12","unstructured":"Oxygen-induced retinopathy in the mouse10111\n            SmithLE\n            WesolowskiE\n            McLellanA\n            KostykSK\n            D'AmatoR\n            SullivanR\n          Invest Ophthalmol Vis Sci.351994"},{"key":"B13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1203\/00006450-199412000-00007","article-title":"Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat","volume":"36","author":"Penn","year":"1994","journal-title":"Pediatr Res."},{"key":"B14","unstructured":"Vaso-obliteration in the canine model of oxygen-induced retinopathy30011\n            McLeodDS\n            BrownsteinR\n            LuttyGA\n          8603834Invest Ophthalmol Vis Sci.371996"},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/EB.S94443","article-title":"Targeting VEGF in canine oxygen-induced retinopathy - a model for human retinopathy of prematurity","volume":"8","author":"McLeod","year":"2016","journal-title":"Eye Brain."},{"key":"B16","unstructured":"Localization of VEGF receptor-2 (KDR\/Flk-1) and effects of blocking it in oxygen-induced retinopathy47482\n            McLeodDS\n            TaomotoM\n            CaoJ\n            ZhuZ\n            WitteL\n            LuttyGA\n          11818393Invest Ophthalmol Vis Sci.432002"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature."},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","article-title":"Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice","volume":"376","author":"Shalaby","year":"1995","journal-title":"Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1442-9071.2003.00602.x","article-title":"Vascular endothelial growth factor-B and retinal vascular development in the mouse","volume":"31","author":"Reichelt","year":"2003","journal-title":"Clin Exp Ophthalmol."},{"key":"B22","unstructured":"VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: Relevance to clinical ROP51220\n            McColmJR\n            GeisenP\n            HartnettME\n          15303088Mol Vis.102004"},{"key":"B23","first-page":"345","article-title":"Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity","volume":"14","author":"Geisen","year":"2008","journal-title":"Mol Vis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/archophthalmol.2010.158","article-title":"Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity","volume":"128","author":"Budd","year":"2010","journal-title":"Arch Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/glia.20997","article-title":"Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina","volume":"58","author":"Weidemann","year":"2010","journal-title":"Glia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/path.2611","article-title":"Muller cell-derived VEGF is a significant contributor to retinal neovascularization","volume":"219","author":"Bai","year":"2009","journal-title":"J Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1167\/iovs.13-13755","article-title":"Targeting muller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity","volume":"55","author":"Jiang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ajpath.2013.05.011","article-title":"Short hairpin RNA-mediated knockdown of VEGFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity","volume":"183","author":"Wang","year":"2013","journal-title":"Am J Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41598-018-20278-4","article-title":"Targeted knockdown of overexpressed VEGFA or VEGF164 in muller cells maintains retinal function by triggering different signaling mechanisms","volume":"8","author":"Becker","year":"2018","journal-title":"Sci Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin Perinatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/mvre.1998.2111","article-title":"Increased expression of KDR\/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization","volume":"56","author":"Suzuma","year":"1998","journal-title":"Microvasc Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08977199809017487","article-title":"Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina","volume":"16","author":"Robbins","year":"1998","journal-title":"Growth Factors."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e21411","DOI":"10.1371\/journal.pone.0021411","article-title":"Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nm731","article-title":"Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1","volume":"8","author":"Luttun","year":"2002","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1172\/JCI17808","article-title":"Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity","volume":"112","author":"Shih","year":"2003","journal-title":"J Clin Invest."},{"key":"B41","doi-asserted-by":"publisher","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J Biol Chemistry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood-2006-07-037952","article-title":"Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1182\/blood.V99.7.2397","article-title":"Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division","volume":"99","author":"Kearney","year":"2002","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1167\/iovs.08-1780","article-title":"Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease","volume":"49","author":"Hartnett","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0002-9440(10)64773-6","article-title":"Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization","volume":"156","author":"Ozaki","year":"2000","journal-title":"Am J Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1096\/fj.00-0598fje","article-title":"Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development","volume":"15","author":"Robinson","year":"2001","journal-title":"FASEB J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10456-018-9618-5","article-title":"Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy","volume":"21","author":"Simmons","year":"2018","journal-title":"Angiogenesis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0012-1606(87)90335-6","article-title":"Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies","volume":"122","author":"Takagi","year":"1987","journal-title":"Dev Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0896-6273(00)80371-2","article-title":"Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III","volume":"19","author":"Chen","year":"1997","journal-title":"Neuron."},{"key":"B50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s0092-8674(00)80534-6","article-title":"Neuropilin is a receptor for the axonal chemorepellent Semaphorin III","volume":"90","author":"He","year":"1997","journal-title":"Cell."},{"key":"B51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s1050-1738(01)00140-2","article-title":"The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis","volume":"12","author":"Neufeld","year":"2002","journal-title":"Trends Cardiovasc Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrc2404","article-title":"The semaphorins: versatile regulators of tumour progression and tumour angiogenesis","volume":"8","author":"Neufeld","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J."},{"key":"B54","unstructured":"Colocalization of neuropilin-1 and flk-1 in retinal neovascularization in a mouse model of retinopathy11728\n            IshihamaH\n            OhbayashiM\n            KurosawaN\n            KitsukawaT\n            MatsuuraO\n            MiyakeY\n          11328724Invest Ophthalmol Vis Sci.422001"},{"key":"B55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1073\/pnas.012074399","article-title":"Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis","volume":"99","author":"Oh","year":"2002","journal-title":"Proc Nat Acad Sci U S A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.15252\/emmm.201404922","article-title":"Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis","volume":"7","author":"Yang","year":"2015","journal-title":"EMBO Mol Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2119\/2004-00017.Campochiaro","article-title":"Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization","volume":"10","author":"Shen","year":"2004","journal-title":"Mol Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archophthalmol.2010.65","article-title":"Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity","volume":"128","author":"Budd","year":"2010","journal-title":"ArchOphthalmol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1242\/dev.126.21.4895","article-title":"A requirement for neuropilin-1 in embryonic vessel formation","volume":"126","author":"Kawasaki","year":"1999","journal-title":"Development."},{"key":"B60","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/s0896-6273(00)80392-x","article-title":"Neuropilin-semaphorin III\/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice","volume":"19","author":"Kitsukawa","year":"1997","journal-title":"Neuron."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1042\/BST20140244","article-title":"Neuropilin regulation of angiogenesis","volume":"42","author":"Lampropoulou","year":"2014","journal-title":"Biochem Soc Trans."},{"key":"B62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.02.003","article-title":"NRP1 function and targeting in neurovascular development and eye disease","volume":"52","author":"Raimondi","year":"2016","journal-title":"Prog Retin Eye Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1167\/iovs.15-18598","article-title":"Neuropilin-1-expressing microglia are associated with nascent retinal vasculature yet dispensable for developmental angiogenesis","volume":"57","author":"Dejda","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1242\/dev.070037","article-title":"The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins","volume":"138","author":"Fantin","year":"2011","journal-title":"Development."},{"key":"B65","doi-asserted-by":"publisher","first-page":"25520","DOI":"10.1074\/jbc.M102315200","article-title":"Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121","volume":"276","author":"Whitaker","year":"2001","journal-title":"J Biol Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jcb.10140","article-title":"VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding","volume":"85","author":"Soker","year":"2002","journal-title":"J Cell Biochem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"25110","DOI":"10.1074\/jbc.C800137200","article-title":"Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1","volume":"283","author":"Prahst","year":"2008","journal-title":"J Biol Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1242\/dev.103028","article-title":"Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis","volume":"141","author":"Fantin","year":"2014","journal-title":"Development."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0002-9440(10)63001-5","article-title":"Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy","volume":"167","author":"Al-Shabrawey","year":"2005","journal-title":"Am J Pathol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000336639","article-title":"Reduction of retinopathy of prematurity in extremely low gestational age newborns treated with recombinant human Cu\/Zn superoxide dismutase","volume":"102","author":"Parad","year":"2012","journal-title":"Neonatology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0022-3476(97)70031-3","article-title":"Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials","volume":"131","author":"Raju","year":"1997","journal-title":"J Pediatrics."},{"key":"B73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1542\/peds.75.4.619","article-title":"Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1,500 grams or less","author":"Johnson","year":"1985","journal-title":"Pediatrics"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1167\/iovs.13-12171","article-title":"Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy in the rat 50\/10 model","volume":"54","author":"Trichonas","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"19898","DOI":"10.1073\/pnas.0805817105","article-title":"Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy","volume":"105","author":"Sears","year":"2008","journal-title":"Proc Nat Acad Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaapos.2012.12.155","article-title":"Effects of oxygen on the development and severity of retinopathy of prematurity","volume":"17","author":"Hartnett","year":"2013","journal-title":"J AAPOS."},{"key":"B77","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000330174","article-title":"Understanding retinopathy of prematurity: update on pathogenesis","volume":"100","author":"Rivera","year":"2011","journal-title":"Neonatology."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.796143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:59:17Z","timestamp":1639054757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.796143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":77,"alternative-id":["10.3389\/fped.2021.796143"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.796143","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]},"article-number":"796143"}}